Andrea GS Pepper, PhD^1*, Antonella Zucchetto, PhD^2*, Kevin Norris, PhD^3*, Erika Tissino, PhD^4*, Jerry Polesel^5*, Zarni Soe^6*, David Allsup^7*, Anna Hockaday^8*, Pei Loo Ow^9*, Peter Hillmen, MBChB, PhD^10*, Andrew Rawstron, PhD^11*, Daniel Catovsky, MD, FRCP¹², Riccardo Bomben, PhD^2*, Duncan M Baird, PhD^13*, Christopher Fegan^14*, Valter Gattei, MD¹⁵ and Chris Pepper, BSc, PhD¹⁶

¹University of Sussex, Brighton and Sussex Medical School, Falmer, GBR
²Clinical and Experimental Onco-Hematology Unit, IRCCS Centro Di Riferimento Oncologico, Aviano, Italy
³Division of Cancer & Genetics, Cardiff University, Cardiff, United Kingdom
⁴Clinical and Experimental Onco-Hematology Unit, IRCCS Centro Di Riferimento Oncologico, Aviano, Pn, Italy
⁵Unit of Cancer Epidemiolog, IRCCS Centro Di Riferimento Oncologico, Aviano, Italy
⁶Haematology, Leeds Teaching Hospital Trust, Leeds, United Kingdom
⁷Centre for Atherothrombosis and Metabolic Disease, Hull York Medical School, Hull, ENG, United Kingdom
⁸Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, Leeds, United Kingdom
⁹University of Leeds, Leeds, GBR
¹⁰Department of Haematology, St James University Hospital, Leeds, United Kingdom
¹¹HMDS, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom
¹²The Institute of Cancer Research, London, United Kingdom
¹³Division of Cancer and Genetics, Cardiff University, Cardiff, United Kingdom
¹⁴School of Medicine, Division of Cancer and Genetics, Cardiff University, Cardiff, United Kingdom
¹⁵Clinical and Experimental Onco-Hematology Unit, Centro Di Riferimento Oncologico, Aviano, Italy
¹⁶Brighton and Sussex Medical School, University of Sussex, Brighton, United Kingdom

Erin Michelle Parry, MD, PhD¹, Romain Guieze, MD^2,3*, Ignaty Leshchiner, PhD^4*, Daniel Rosebrock^4*, Bria Persaud^5*, Camilla K Lemvigh, MSc^6*, Eugen Tausch, MD^7*, Matthew S. Davids, MD⁸, Johannes Bloehdorn, MD^9*, Christof Schneider, MD^10*, Liudmila Elagina^4*, Aina Zurita Martinez^4*, Amaro Taylor-Weiner, PhD^5*, Nitin Jain, MD¹¹, William G. Wierda, MD, PhD¹², Laura Z. Rassenti, PhD¹³, Thomas J. Kipps, MD, PhD¹³, Julien Broséus, Dr^14*, Florence Cymbalista, MD, PhD^15*, Neil E. Kay, MD¹⁶, Kenneth J. Livak, PhD^17*, Shuqiang Li, PhD^17*, Teddy Huang, BS^17*, Noelia Purroy, MD, PhD^1*, Annabelle J Anandappa, MD^1,18, Stacey M. Fernandes, BS^19*, Filippo Utro, PhD^20*, Kahn Rhrissorrakrai, PhD^20*, Chaya Levovitz, MD, PhD^20*, Brian P Danysh, PhD^5*, Kara Slowik^5*, Sameer A. Parikh, MD¹⁶, Jennifer R Brown, MD, PhD^19,21,22, Laxmi Parida, PhD^20*, Donna S. Neuberg, ScD²³, Stephan Stilgenbauer, MD²⁴, Gad Getz, PhD^4,25,26* and Catherine J. Wu, MD^1,4,25

¹Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
²Université Clermont Auvergne, Clermont-Ferrand, France
³Service d'Hématologie Clinique et Thérapie Cellulaire, CHU, Université Clermont Auvergne EA7453 Chelter CIC-1405, Clermont-Ferrand, France
⁴Broad Institute of MIT and Harvard, Cambridge, MA
⁵Broad Institute of Harvard and MIT, Cambridge, MA
⁶Department of Department of Health Technology, Technical University of Denmark, Lyngby, Denmark
⁷Department III of Internal Medicine, Ulm University, Ulm, Germany
⁸Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA
⁹Department of Internal Medicine III, University Hospital Ulm, Ulm, Germany
¹⁰Department of Internal Medicine III, Ulm University, Ulm, Germany
¹¹Associate Professor of Medicine Department of Leukemia The University of Texas MD Anderson Cancer Center, Houston, TX
¹²Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX
¹³Moores Cancer Center, University of California, San Diego, La Jolla, CA
¹⁴Laboratory Department, CHRU Nancy, Vandoeuvre-lès-Nancy, France
¹⁵Laboratoire d'Hématologie, APHP Hôpital Avicenne, Bobigny, France
¹⁶Division of Hematology, Mayo Clinic, Rochester, MN
¹⁷Translational Immunogenomics Lab, Dana-Farber Cancer Institute, Boston, MA
¹⁸Department of Medicine, Massachusetts General Hospital, Boston, MA
¹⁹Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
²⁰IBM T.J. Watson Research Center, Yorktown Heights, NY
²¹CLL Center, Dana-Farber Cancer Institute, Boston, MA
²²Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
²³Department of Data Science, Dana-Farber Cancer Institute, Boston, MA
²⁴University of Ulm, Ulm, Germany
²⁵Harvard Medical School, Boston, MA
²⁶Cancer Center and Department of Pathology, Massachusetts General Hospital, Boston, MA

Zhiquan Wang, PhD¹, Justin C. Boysen^1*, Huihuang Yan, PhD^2*, Charla R. Secreto^1*, Sameer A. Parikh, MD¹, Saad S. Kenderian, MD¹, Wei Ding, MD, PhD¹, Esteban Braggio, PhD³, Susan L. Slager, PhD^2* and Neil E. Kay, MD¹

¹Division of Hematology, Mayo Clinic, Rochester, MN
²Department of Health Sciences Research, Mayo Clinic, Rochester, MN
³Division of Hematology/Oncology, Mayo Clinic, Scottsdale, AZ

Daniel Goldstein, MD^1*, Kyle A. Beckwith, MD PhD², Cecelia Miller, PhD^3*, Ying Huang, MS, MA^2*, Lynne V. Abruzzo, MD, PhD³, Seema A Bhat, MD², David A. Bond, MD, BS⁴, John C. Byrd, MD², Michael R. Grever, MD², Nyla A Heerema, PhD³, Kerry A. Rogers, MD^2*, Amy S. Ruppert, PhD², Jennifer A. Woyach, MD² and Adam S. Kittai, MD²

¹Department of Internal Medicine, The Ohio State University, Columbus, OH
²Division of Hematology, The Ohio State University, Columbus, OH
³Department of Pathology, The Ohio State University, Columbus, OH
⁴Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH

Charline Moulin^1*, Francis Guillemin, MD, PhD^1*, Thomas Remen^2*, Florian Bouclet^3*, Hélène Augé^4*, Anne Quinquenel, MD, PhD^5*, Caroline Dartigeas, MD^6*, Romain Morizot^4*, Sandra Lomazzi^7*, Hélène Busby, MD^8*, Sebastien Hergalant^9*, Eugen Tausch, MD^10*, Cécile Tomowiak, MD^11*, Veronique Leblond, MD, PhD^12*, Catherine Thieblemont, MD, PhD¹³, Florence Cymbalista, MD, PhD^14*, Kamel Laribi, MD^15*, Marie C Bene, PharmSci, PhD^16*, Stephan Stilgenbauer, MD¹⁷, Romain Guieze, MD^18*, Pierre Feugier, MD, PhD^19* and Julien Broséus, Dr^20*

¹CIC-EC 1433, Nancy University Hospital, VANDOEUVRE, France
²Unit of Methodology and Statistics, Nancy University Hospital, VANDOEUVRE, France
³CHU Estaing, Unit of adult cell therapy and clinical hematology, University Hospital of Clermont-Ferrand, Clermont-Ferrand, Auvergne, France
⁴Haematology Department, Nancy University Hospital, Vandoeuvre-lès-Nancy, France
⁵Haematology Department, Robert Debré University Hospital, Reims, France
⁶CHU Tours, Tours, France
⁷Biocollection repository, Nancy University Hospital, Vandoeuvre-lès-Nancy, France
⁸Pathology Department, Nancy University Hospital, Vandoeuvre-lès-Nancy, France
⁹U1256, Inserm, Vandoeuvre-lès-Nancy, France
¹⁰Department of Internal Medicine III, Ulm University, Ulm, Germany
¹¹Department of Oncology-Haematology and Cell Therapy, University Hospital of Poitiers, Poitiers, France
¹²Département d’ Hématologie Hôpital Pitié-Salpêtrière APHP, UPMC Université Paris, Paris, France
¹³Hôpital Saint-Louis, Paris, France
¹⁴Laboratoire d'Hématologie, APHP Hôpital Avicenne, Bobigny, France
¹⁵Centre Hospitalier Du Mans, Le Mans, France
¹⁶CRCINA, INSERM, CNRS, Université d'Angers, Université de Nantes, Nantes, France
¹⁷Department of Internal Medicine III, University Hospital Ulm, Ulm, Germany
¹⁸CHU Estaing, Unit of adult cell therapy and clinical hematology, University Hospital of Clermont-Ferrand, Brookline, MA
¹⁹Hematology Department, Nancy University Hospital, Vandoeuvre-lès-Nancy, France
²⁰Laboratory Department, CHRU Nancy, Vandoeuvre-lès-Nancy, France

Hua-Jay J Cherng, MD¹, Nadya Jammal, PharmD^2*, Shilpa Paul, PharmD^2*, Xuemei Wang, MS^3*, Koji Sasaki, MD⁴, Philip A. Thompson, MB, MS⁵, Jan A. Burger, MD, PhD⁶, Alessandra Ferrajoli, MD⁷, Zeev E. Estrov, MD⁶, Susan M. O'Brien, MD⁸, Michael J. Keating, MBBS⁷, William G. Wierda, MD, PhD⁹ and Nitin Jain, MD¹⁰

¹Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, TX
²Department of Pharmacy, The University of Texas MD Anderson Cancer Center, Houston, TX
³Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX
⁴Department of Leukemia, MD Anderson Cancer Center, Houston, TX
⁵The University of Texas MD Anderson Cancer Center, Houston, TX
⁶Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
⁷Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX
⁸UCI Cancer Center, Orange, CA
⁹Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX
¹⁰Associate Professor of Medicine Department of Leukemia The University of Texas MD Anderson Cancer Center, Houston, TX

Nadine Abdallah, MD^1*, Angela Dispenzieri, MD^2*, Eli Muchtar, MD^3*, Francis K. Buadi, MB, CHB^3*, Prashant Kapoor, MD³, Martha Q. Lacy, MD³, Yi L. Hwa, NP², Amie Fonder, PA-C, MS^2*, Miriam A. Hobbs, APRN, CNP, DNP^2*, Suzanne R. Hayman, MD², Nelson Leung, MD³, David Dingli, MD, PhD³, John A. Lust, MD, PhD², Ronald S. Go, MD⁴, Yi Lin, MD, PhD², Wilson I Gonsalves, MD³, Taxiarchis Kourelis, MD³, Rahma M Warsame, MD⁵, Robert A. Kyle, MD³, S. Vincent Rajkumar, MD³, Morie A Gertz, MD² and Shaji K. Kumar, MD²

¹Department of Internal Medicine, Division of Hematology and Oncology, Mayo Clinic, Rochester, MN
²Division of Hematology, Mayo Clinic, Rochester, MN
³Mayo Clinic Rochester, Division of Hematology, Rochester, MN
⁴Mayo Clinic Rochester, Division of Hematology, Onalaska, WI
⁵Mayo Clinic, Rochester, MN

Segun C Jung, PhD^1*, Maya Thangavelu, PhD¹, Hyunjun Nam, PhD^2*, Ryan Bender, PhD, FACMGG^2*, Sally Agersborg, MD, PhD^1*, Lawrence Weiss, MD^1* and Vincent Funari, PhD^1*

¹NeoGenomics Laboratories, Inc., Aliso Viejo, CA
²NeoGenomics Laboratories, Inc., Carlsbad, CA

Shanye Yin, PhD^1*, Gregory Lazarian, PharmD^2,3*, Elisa Ten Hacken, PhD⁴, Tomasz Sewastianik, PhD^5*, Satyen Gohil, BSc, MBBS, MRCP, FRCPath⁶, Shuqiang Li, PhD^1,7*, Laura Z. Rassenti, PhD⁸, Leah Billington, BA^1*, Elizabeth Witten^1*, Teddy Huang, BS^7*, Kenneth J. Livak, PhD^1,7*, Donna S. Neuberg, ScD⁹, Fanny Baran-Marszak, MD, PhD^3*, Thomas J. Kipps, MD, PhD¹⁰, Florence Cymbalista, MD, PhD^3*, Ruben D. Carrasco, MD, PhD^11,12* and Catherine J. Wu, MD^1,13,14

¹Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
²Department of Medical Oncology, Dana-Farber Cancer Institute, PARIS, France
³Laboratoire d'Hématologie, APHP Hôpital Avicenne, Bobigny, France
⁴Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA
⁵Dept. of Experimental Hematology, Institute of Hematology and Transfusion Medicine, Warsaw, Poland
⁶University Ci, Enfield, United Kingdom
⁷Translational Immunogenomics Lab, Dana-Farber Cancer Institute, Boston, MA
⁸Moores Cancer Center, University of California, San Diego, La Jolla, CA
⁹Department of Data Sciences, Dana-Farber Cancer Institute, Boston, MA
¹⁰UCSD Moores Cancer Center, San Diego, CA
¹¹Department of Oncologic Pathology, Dana-Farber Cancer Institute, Boston, MA
¹²Dept. of Pathology, Brigham and Women's Hospital, Boston, MA
¹³Broad Institute of MIT and Harvard, Cambridge, MA
¹⁴Dana-Farber Cancer Institute, Boston, MA